Lusutrombopag - CISMeF

Preferred Label : Lusutrombopag;

NCIt definition : An orally available thrombopoietin (TPO) receptor (TPOR; MPL) agonist, with potential megakaryopoiesis stimulating activity. Upon administration, lusutrombopag binds to and interacts with the transmembrane domain of human TPO receptor expressed on megakaryocytes, which leads to the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells. This increases the production of platelets and may prevent or treat thrombocytopenia in patients with chronic liver disease. TPOR is a cytokine receptor and member of the hematopoietic receptor superfamily.;

UNII : 6LL5JFU42F;

InChIKey : NOZIJMHMKORZBA-KJCUYJGMSA-N;

CAS number : 1110766-97-6;

Drug name : Mulpleo; Mulpleta;

NCI Metathesaurus CUI : CL972196;

Codes from synonyms : 315;

Details

Origin ID

C166948;

UMLS CUI

C4309207;

Automatic exact mappings (from CISMeF team)
- Lusutrombopag (substance) [SNOMED CT concept]
- lusutrombopag [MeSH Supplementary Concept]
- lusutrombopag [ATC Code]
- lusutrombopag [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Lusutrombopag (substance) [SNOMED CT concept]
- Product containing lusutrombopag (medicinal product) [SNOMED CT concept]
- lusutrombopag [ATC Code]
- lusutrombopag [MeSH Supplementary Concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients